This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shao, J. Articles by Yen, Y. Search for Related Content PubMed PubMed Citation Articles by Shao, J. Articles by Yen, Y.

In Vitro Characterization of Enzymatic Properties and Inhibition of the p53R2 Subunit of Human Ribonucleotide Reductase

¹Departments of Medical Oncology and Therapeutic Research and ²Bioinformatics, City of Hope National Medical Center, Duarte, California, and ³Department of Basic Medical Science, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China

p53R2 is a newly identified subunit of ribonucleotide reductase (RR) and plays a crucial role in supplying precursors for DNA repair in a p53-dependent manner. In our current work, all three human RR subunit proteins (p53R2, hRRM2, and hRRM1) were prokaryotically expressed and highly purified. Using an in vitro [³H]CDP reduction assay, the activity of RR reconstituted with either p53R2 or hRRM2 was found to be time, concentration, and hRRM1 dependent. The kinetic activity of p53R2-containing RR was about 20–50% lower than that of hRRM2-containing RR. Using a synthetic heptapeptide to inhibit RR activity, it was shown that p53R2 bound to hRRM1 through the same COOH-terminal heptapeptide as hRRM2. However, hRRM2 had a 4.76-fold higher binding affinity for hRRM1 than p53R2, which may explain the reduced RR activity of p53R2 relative to hRRM2. Of interest, p53R2 was 158-fold more susceptible to the iron chelator deferoxamine mesylate than hRRM2, although the iron content of the two proteins determined by atomic absorption spectrometer was almost the same. To the contrary, p53R2 was 2.50-fold less sensitive than hRRM2 to the radical scavenger hydroxyurea, whereas EPR showed similar spectra of the tyrosyl radical in two proteins. Triapine, a new RR inhibitor, was equally potent for p53R2 and hRRM2. These inhibition studies showed that the iron center and tyrosyl radical are involved in RR activity for both p53R2 and hRRM2. The susceptibility differences to RR inhibitors between p53R2 and hRRM2 may lead to a new direction in drug design for human cancer treatment.

This article has been cited by other articles:

				J. Wang, G. J. S. Lohman, and J. Stubbe Enhanced subunit interactions with gemcitabine-5'-diphosphate inhibit ribonucleotide reductases PNAS, September 4, 2007; 104(36): 14324 - 14329. [Abstract] [Full Text] [PDF]

				S. Y. Rha, H. C. Jeung, Y. H. Choi, W. I. Yang, J. H. Yoo, B. S. Kim, J. K. Roh, and H. C. Chung An Association Between RRM1 Haplotype and Gemcitabine-Induced Neutropenia in Breast Cancer Patients Oncologist, June 1, 2007; 12(6): 622 - 630. [Abstract] [Full Text] [PDF]

				Y. Yu, J. Wong, D. B. Lovejoy, D. S. Kalinowski, and D. R. Richardson Chelators at the Cancer Coalface: Desferrioxamine to Triapine and Beyond Clin. Cancer Res., December 1, 2006; 12(23): 6876 - 6883. [Abstract] [Full Text] [PDF]

				X. Liu, B. Zhou, L. Xue, J. Shih, K. Tye, W. Lin, C. Qi, P. Chu, F. Un, W. Wen, et al. Metastasis-Suppressing Potential of Ribonucleotide Reductase Small Subunit p53R2 in Human Cancer Cells. Clin. Cancer Res., November 1, 2006; 12(21): 6337 - 6344. [Abstract] [Full Text] [PDF]

				C. A. Barker, W. E. Burgan, D. J. Carter, D. Cerna, D. Gius, M. G. Hollingshead, K. Camphausen, and P. J. Tofilon In vitro and In vivo Radiosensitization Induced by the Ribonucleotide Reductase Inhibitor Triapine (3-Aminopyridine-2-Carboxaldehyde-Thiosemicarbazone). Clin. Cancer Res., May 1, 2006; 12(9): 2912 - 2918. [Abstract] [Full Text] [PDF]

				J. Shao, B. Zhou, A. J. Di Bilio, L. Zhu, T. Wang, C. Qi, J. Shih, and Y. Yen A Ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol. Cancer Ther., March 1, 2006; 5(3): 586 - 592. [Abstract] [Full Text] [PDF]

				L. Xue, B. Zhou, X. Liu, T. Wang, J. Shih, C. Qi, Y. Heung, and Y. Yen Structurally Dependent Redox Property of Ribonucleotide Reductase Subunit p53R2 Cancer Res., February 15, 2006; 66(4): 1900 - 1905. [Abstract] [Full Text] [PDF]

				D. S. Kalinowski and D. R. Richardson The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer Pharmacol. Rev., December 1, 2005; 57(4): 547 - 583. [Abstract] [Full Text] [PDF]

				B. Zhou, J. Shao, L. Su, Y.-C. Yuan, C. Qi, J. Shih, B. Xi, B. Chu, and Y. Yen A dityrosyl-diiron radical cofactor center is essential for human ribonucleotide reductases Mol. Cancer Ther., December 1, 2005; 4(12): 1830 - 1836. [Abstract] [Full Text] [PDF]

				Z. P. Lin, M. F. Belcourt, J. G. Cory, and A. C. Sartorelli Stable Suppression of the R2 Subunit of Ribonucleotide Reductase by R2-targeted Short Interference RNA Sensitizes p53(-/-) HCT-116 Colon Cancer Cells to DNA-damaging Agents and Ribonucleotide Reductase Inhibitors J. Biol. Chem., June 25, 2004; 279(26): 27030 - 27038. [Abstract] [Full Text] [PDF]

				S. Yamaoka, M. Miyaji, T. Kitano, H. Umehara, and T. Okazaki Expression Cloning of a Human cDNA Restoring Sphingomyelin Synthesis and Cell Growth in Sphingomyelin Synthase-defective Lymphoid Cells J. Biol. Chem., April 30, 2004; 279(18): 18688 - 18693. [Abstract] [Full Text] [PDF]